Coronary heart disease
Conditions
Interventions
Protamine group:If ACT is less than 150 seconds, no protamine is given
if 150 <= ACT < 200 seconds, (total dose of heparin (mg) / 2 - 10) mg of protamine is given
if 200 <= ACT < 250 seconds, (total dose of heparin (mg) / 2) mg of protamine is given
if 250 <= ACT < 300 seconds, (total dose of heparin (mg) / 2 + 10) mg of protamine is given
if ACT is greater than or equal to 300 seconds, (total dose of heparin (mg) / 2 + 20) mg of protamine is given
Control group:Heparin is naturally metabolized from the body
Sponsors
The Sixth Medical Center of the Chinese People's Liberation Army General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18, of either gender; 2. Both aspirin and ticagrelor were administered as premedication before surgery; 3. Patients with acute coronary syndrome (ACS), including unstable angina, non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction; 4. For patients who are clinically diagnosed and require PCI treatment, the coronary intervention puncture sites include the radial artery, brachial artery, or femoral artery; 5. Use unfractionated heparin as an anticoagulant during the procedure; 6. The patient or their legal guardian signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with severe allergy to heparin/protamine; 2. Moderate-to-severe pulmonary hypertension and moderate-to-severe heart valve disease; 3. Severe liver dysfunction (Child-Pugh Class C); 4. Severe renal dysfunction (most commonly defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2); 5. Preoperative active bleeding or abnormal coagulation function; 6. Platelet count <100×10^9/L; 7. Participate in other clinical trials that may affect the results of this study; 8. Refusal to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding Complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stent thrombosis and target lesion thrombosis;Protamine-related adverse events;Major cardiovascular events (MACE); | — |
Countries
China
Contacts
Public ContactWang Qi
The Sixth Medical Center of the Chinese People's Liberation Army General Hospital
Outcome results
None listed